Cortiva®
ALLOGRAFT DERMIS

Gentle processing, rapid incorporation

Cortiva® allograft dermis' proprietary processing maintains the native dermal structure and has been shown to support robust revascularization and rapid incorporation of the graft.[1,2,3,4,†,*]



Native dermal structure

The proprietary processing used across the Cortiva® allograft dermis portfolio — including Cortiva Silhouette®, Cortiva® 1mm Perforated Tailored, Cortiva® 1mm Tailored, Cortiva® 1mm Perforated and Cortiva® 1mm allograft dermis — is validated to inactivate and/or remove a broad panel of viruses, bacteria, fungi, and spores, while preserving the native dermal structure and biomechanical characteristics.[1,*]

Unprocessed human dermis[1]

Cortiva®
ALLOGRAFT DERMIS



Processing removes cellular and DNA content (DAPI nuclear DNA stain. 20× magnification.)

Unprocessed human dermis[1]

Cortiva®
ALLOGRAFT DERMIS



H&E staining shows the preserved native structure in Cortiva® allograft dermis. Cells removed. Processing leaves native tissue intact (H&E Stain. 50× magnification.)

Rapid graft incorporation

In a clinical setting, 13 patients underwent a second planned procedure during which the graft was biopsied, and robust revascularization and incorporation were observed.[2,†]

Biopsy with Cortiva® allograft dermis at reoperation (100×)



Image: Representative Masson's Trichrome histology.

B Blood vessels

▶ Cellular infiltration



Level 1 clinical evidence results

In a prospective randomized controlled trial of 302 patients, outcomes with Cortiva® 1mm allograft dermis (151 patients) were compared to outcomes with AlloDerm RTM (151 patients). The study noted that the odds of seroma formation were nearly twice as high with AlloDerm RTM than with Cortiva® 1mm allograft dermis (p=0.047) after adjustment for relevant covariates.[4,†]

	Seroma	Hematoma	Infection	Necrosis	Dehiscence	Reconstructive failure
Cortiva® 1MM ALLOGRAFT DERMIS	**21 (7.6%)**	4 (1.4%)	24 (8.7%)	17 (6.1%)	14 (5.1%)	23 (8.3%)
AlloDerm RTM	**33 (12%)**	10 (3.6%)	26 (9.3%)	22 (7.9%)	16 (5.7%)	26 (9.3%)
p-Value	**0.09**	0.17	0.80	0.43	0.73	0.68

Precise thickness consistency of ± 0.1–0.125mm.[1]

Measured every 2cm for consistent thickness.[1]

Length and width confirmed twice with a laser-calibrated ruler.[1]

Conforms to specifications without deviation. Graft measurements are not averaged.

For more information, visit **CortivaADM.com**

Cortiva®
ALLOGRAFT DERMIS

References

1. Data on file at Evergen.
2. Moyer, et. al. 2017. "A histological comparison of two human acellular dermal matrix products in prosthetic-based breast reconstruction." Plastic and Reconstructive Surgery Global Open, December 2017, 5(12).
3. Gierek M, et. al. "Human Acellular Dermal Matrix in Reconstructive Surgery - A Review." Biomedicines. 2022 Nov 9;10(11):2870.
4. Keane AM, Chiang SN, Tao Y, Pierce A, Gagne J, Margenthaler JA, Tenenbaum MM, Myckatyn TM. "Cortiva vs AlloDerm in Prepectoral and Partial Submuscular Implant-Based Breast Reconstruction: A Randomized Clinical Trial." Plast Reconstr Surg. 2023 Dec 12.

† Clinical cases are unique and individual results may vary.
* Performance data from animal models may not be representative of performance in humans.

All Cortiva® and Cortiva Silhouette® allograft dermis implants are processed by RTI Surgical, Inc. (Alachua, FL).
Please refer to the labeling for complete instructions for use. Regulatory approvals vary by country. Therefore, we kindly ask you to contact the representative in your region regarding the availability of specific grafts in your country.

Distributed by:
Evergen
11621 Research Circle
Alachua, FL 32615 USA
T 800.624.7238
evergenbio.com

13194 R04